Anti-TNF drugs may be associated with various adverse reactions including cutaneous ones. We describe the case of a 45-year-old woman affected by undifferentiated spondylarthritis who presented a localized psoriasiformis dermatitis during treatment with adalimumab, without any medical history of psoriasis.
TammaroANarcisiADi RussoPPAbruzzeseCDe MarcoGPersechinoFParisellaFRPersechinoS. Contact allergy to limonene from a home-made cosmetic. Eur J Inflamm (in press)
2.
WollinaUHanselGKochASchonlebeJKostlerEHaroskeG. Tumor necrosis factor-a inhibitor induced psoriasis or psoriasiform exanthemata. First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol2008; 9:1–14.
3.
GottliebAB. Clinical research helps elucidate the role of tumor necrosis factor alpha (TNF-alpha) in the pathogenesis of T1-mediated immune disorders: Use of targeted immunotherapeutics as pathogenetic probes. Lupus2003; 12 (3): 190–4.
4.
FeldmannMMainiRN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med2003; 9(10):1245–50.
5.
Muller-LadnerUAltenRHeiligenhausA. “TRECID”, TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept. Dtsch Med Wochenschr2009; 134:2132–6
6.
CassanoNMastrandreaVPrincipiMLoconsoleFDe TullioNDi LeoAVenaGA. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: A retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents. 2011; 25(2):285–9.
7.
BordignonVBultriniSPrignanoG. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer. J Biol Regul Homeost Agents2011; 25(2):213–20.
8.
ExarchouSAVoulgariPVMarkatseliTEZiogaADrososAA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol2009; 38(5):328–31.
9.
KarySWormMAudringH. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor a antagonists. Ann Rheum Dis2006; 65:405–7.
10.
TakahashiHHashimotoYIshida-YamamotoAAshidaTKohgoYIizukaH. Psoriasiform and pustular eruption induced by infliximab. J Dermatol2007; 34:446–72.
11.
LeeHHSongIHFriedrichM. Cutaneous side effects in patients with rheumatic diseases during application of tumor necrosis factor-a antagonists. Br J Dermatol2007; 156:486–91
12.
KarySWormMAudringH. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor a antagonists. Ann Rheum Dis2006; 65:405–7.
13.
FeldmannM. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol2002; 2:364–71.
